Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

C. Massard, Joaquı́n Mateo, Yohann Loriot, Carmel Pezaro, Laurence Albigès, Niven Mehra, Andreea Varga, Diletta Bianchini, Christopher Ryan, Daniel P. Petrylak,

Annals of Oncology · 2016 · 28 citations · 19 references

DOIFull text

Open access

Concepts

References

19